Table 1.

Baseline characteristics of individuals in cohorts participating in the 2-year observation period for change in eGFR over time stratified by baseline eGFR

CohortNAge, yrWomen, %Black, %eGFR, ml/min per 1.73 m2SBP, mm HgDiabetes, %History of CVD, %Current smoker, %Former smoker, %TC, mmol/L
eGFR<60
 AASK74454 (11)3910042 (11)150 (24)05344285.5 (1.1)
 BC CKD895070 (13)46032 (11)136 (23)44242.66.1NAa
 CCF18,87372 (11)551247 (10)131 (19)25250.22.34.7 (1.1)
 Geisinger19,20073 (12)620.847 (11)134 (20)28428.4275.0 (1.1)
 KP Hawaii546871 (11)53047 (10)137 (22)52357.4NA4.7 (1.1)
 Maccabi29,21174 (11)50049 (10)134 (19)32471.09194.8 (1.1)
 MASTERPLAN51361 (12)31036 (11)136 (20)243021534.8 (1.1)
 MDRD59152 (12)386.635 (11)132 (18)3.91310NA5.6 (1.1)
 NZDCS191371 (9)57048 (10)142 (21)1001.78.1335.3 (1.2)
 RENAAL113960 (7)371438 (11)NA100NA17.2NANA
 SCREAM35,04969 (10)61048 (10)NA1536NANA5.2 (1.2)
 Sunnybrook101370 (13)42035 (12)NA52167.219NA
 Subtotal122,66471 (11)56347 (10)134 (20)28374.2185.0 (1.2)
eGFR 60+
 ADVANCE845766 (6)400.483 (13)144 (21)1002416275.2 (1.2)
 Geisinger138,68255 (15)561.792 (17)128 (18)161517245.1 (1.0)
 KP Hawaii15,14058 (13)49086 (16)135 (20)671613NA4.8 (1.2)
 Maccabi720,01247 (16)590101 (17)124 (17)992.1235.0 (1.0)
 NZDCS709359 (13)490.1186 (16)138 (19)1000.5416305.4 (1.1)
 RCAV2,408,81461 (13)5.916.883 (15)134 (18)2720NANANA
 SCREAM460,35348 (15)54097 (17)NA6.28.7NANA5.4 (1.1)
 Subtotal3,758,55156 (15)241189 (18)132 (18)21165.0235.0 (1.1)
 Total3,881,21557 (15)251187 (19)132 (19)21174.9235.0 (1.1)
  • CVD, cardiovascular disease; SBP, systolic BP; TC, total cholesterol.

  • a Variables missing >50% were marked not available (NA).